Taisho Pharmaceutical Holdings Co Ltd (TAIPY)
12.00
0.00 (0.00%)
USD |
OTCM |
Jul 02, 16:00
Taisho Pharmaceutical Holdings Revenue (Quarterly): 566.03M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 566.03M |
| September 30, 2023 | 569.73M |
| June 30, 2023 | 588.85M |
| March 31, 2023 | 558.06M |
| December 31, 2022 | 589.80M |
| September 30, 2022 | 546.16M |
| June 30, 2022 | 533.05M |
| March 31, 2022 | 586.64M |
| December 31, 2021 | 614.81M |
| September 30, 2021 | 602.15M |
| June 30, 2021 | 583.64M |
| March 31, 2021 | 640.58M |
| December 31, 2020 | 653.47M |
| September 30, 2020 | 667.85M |
| June 30, 2020 | 697.58M |
| March 31, 2020 | 709.73M |
| December 31, 2019 | 727.51M |
| September 30, 2019 | 671.06M |
| June 30, 2019 | 549.01M |
| March 31, 2019 | 557.93M |
| December 31, 2018 | 624.13M |
| September 30, 2018 | 607.58M |
| June 30, 2018 | 567.00M |
| March 31, 2018 | 598.31M |
| December 31, 2017 | 684.45M |
| Date | Value |
|---|---|
| September 30, 2017 | 626.11M |
| June 30, 2017 | 616.83M |
| March 31, 2017 | 557.58M |
| December 31, 2016 | 690.65M |
| September 30, 2016 | 698.94M |
| June 30, 2016 | 642.96M |
| March 31, 2016 | 568.96M |
| December 31, 2015 | 647.89M |
| September 30, 2015 | 626.45M |
| June 30, 2015 | 570.14M |
| March 31, 2015 | 578.23M |
| December 31, 2014 | 697.57M |
| September 30, 2014 | 706.20M |
| June 30, 2014 | 669.75M |
| March 31, 2014 | 662.61M |
| December 31, 2013 | 828.77M |
| September 30, 2013 | 773.03M |
| June 30, 2013 | 690.08M |
| March 31, 2013 | 705.18M |
| December 31, 2012 | 988.64M |
| September 30, 2012 | 917.88M |
| June 30, 2012 | 844.83M |
| March 31, 2012 | 758.43M |
| December 31, 2011 | 1.007B |
| September 30, 2011 | 886.41M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
533.05M
Minimum
Jun 2022
727.51M
Maximum
Dec 2019
617.04M
Average
595.98M
Median
Revenue (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 7.081B |
| Nxera Pharma Co Ltd | 31.07M |
| PeptiDream Inc | 28.47M |
| Healios KK | 0.0674M |
| AnGes Inc | 0.7651M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 19.46M |
| Total Expenses (Quarterly) | 548.03M |
| EPS Diluted (Quarterly) | 1.621M |
| Enterprise Value | -1.710B |
| Gross Profit Margin (Quarterly) | 55.61% |
| Profit Margin (Quarterly) | 3.44% |
| Earnings Yield | 40.16M% |
| Operating Earnings Yield | 92.89M% |